Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OR-101 Phase 1 Study in Healthy Subjects
NCT06045624Phase 1Withdrawn
- Sponsor
- Ornovi
- Start
- Oct 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OR-101 in alopecia areata (4 arms), sponsored by Ornovi. Primary endpoints: Treatment emergent Adverse events, Serious Adverse events and 2 more. Planned start Oct 2023; status: withdrawn.
02
Drugs
OR-101
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06045624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045624.